cd44v6介导的胃癌干细胞调控:一个潜在的治疗靶点

IF 3.2 4区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Hao Chen, Ruoyu Ling, Jiayu Lai, Zhiqi Liu, Zhe Wang, Hua Yang, Yi Kong
{"title":"cd44v6介导的胃癌干细胞调控:一个潜在的治疗靶点","authors":"Hao Chen, Ruoyu Ling, Jiayu Lai, Zhiqi Liu, Zhe Wang, Hua Yang, Yi Kong","doi":"10.1007/s10238-025-01611-4","DOIUrl":null,"url":null,"abstract":"<p><p>Gastric cancer is the fourth most common cause of cancer-related deaths globally. Cancer stem cells (CSCs) play an essential role in tumor initiation, development, and chemoresistance. However, the molecular mechanisms that regulate CSC traits in gastric cancer, particularly the role of CD44v6 as a key CSC marker, remain poorly understood. Here, we demonstrate that CD44v6 is markedly upregulated in gastric cancer tissues and correlates with poor prognosis. Functional assays, including colony formation, wound healing, proliferation, and apoptosis assays, show that CD44v6 enhances CSC characteristics, such as self-renewal, proliferation, migration, and cisplatin chemoresistance. CD44v6 knockdown effectively suppresses these aggressive phenotypes. Mechanistically, CD44v6 regulates the expression of key CSC markers, including CD24, CD133, EpCAM, as well as stemness-related transcription factors Oct-4 and Nanog. Additionally, CD44v6 enhances cell proliferation and drug resistance in both in vitro and in vivo experiments. Collectively, our findings highlight the significant role of CD44v6 in regulating gastric CSC traits, suggesting it's a potential as a biomarker and therapeutic target for improving gastric cancer treatment outcomes, particularly in overcoming chemoresistance.</p>","PeriodicalId":10337,"journal":{"name":"Clinical and Experimental Medicine","volume":"25 1","pages":"80"},"PeriodicalIF":3.2000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897096/pdf/","citationCount":"0","resultStr":"{\"title\":\"CD44v6-mediated regulation of gastric cancer stem cells: a potential therapeutic target.\",\"authors\":\"Hao Chen, Ruoyu Ling, Jiayu Lai, Zhiqi Liu, Zhe Wang, Hua Yang, Yi Kong\",\"doi\":\"10.1007/s10238-025-01611-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Gastric cancer is the fourth most common cause of cancer-related deaths globally. Cancer stem cells (CSCs) play an essential role in tumor initiation, development, and chemoresistance. However, the molecular mechanisms that regulate CSC traits in gastric cancer, particularly the role of CD44v6 as a key CSC marker, remain poorly understood. Here, we demonstrate that CD44v6 is markedly upregulated in gastric cancer tissues and correlates with poor prognosis. Functional assays, including colony formation, wound healing, proliferation, and apoptosis assays, show that CD44v6 enhances CSC characteristics, such as self-renewal, proliferation, migration, and cisplatin chemoresistance. CD44v6 knockdown effectively suppresses these aggressive phenotypes. Mechanistically, CD44v6 regulates the expression of key CSC markers, including CD24, CD133, EpCAM, as well as stemness-related transcription factors Oct-4 and Nanog. Additionally, CD44v6 enhances cell proliferation and drug resistance in both in vitro and in vivo experiments. Collectively, our findings highlight the significant role of CD44v6 in regulating gastric CSC traits, suggesting it's a potential as a biomarker and therapeutic target for improving gastric cancer treatment outcomes, particularly in overcoming chemoresistance.</p>\",\"PeriodicalId\":10337,\"journal\":{\"name\":\"Clinical and Experimental Medicine\",\"volume\":\"25 1\",\"pages\":\"80\"},\"PeriodicalIF\":3.2000,\"publicationDate\":\"2025-03-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11897096/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical and Experimental Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s10238-025-01611-4\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10238-025-01611-4","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

摘要

胃癌是全球癌症相关死亡的第四大常见原因。肿瘤干细胞(CSCs)在肿瘤的发生、发展和化疗耐药中起着重要作用。然而,调控胃癌中CSC特征的分子机制,特别是CD44v6作为关键CSC标志物的作用,仍然知之甚少。在这里,我们证明CD44v6在胃癌组织中显著上调,并与不良预后相关。功能实验,包括菌落形成、伤口愈合、增殖和凋亡实验,表明CD44v6增强了CSC的特性,如自我更新、增殖、迁移和顺铂耐药。CD44v6的敲除有效地抑制了这些侵袭性表型。在机制上,CD44v6调节关键CSC标志物的表达,包括CD24、CD133、EpCAM以及干细胞相关转录因子Oct-4和Nanog。此外,在体外和体内实验中,CD44v6都能增强细胞增殖和耐药。总之,我们的研究结果强调了CD44v6在调节胃CSC特性中的重要作用,表明它有可能作为改善胃癌治疗结果的生物标志物和治疗靶点,特别是在克服化疗耐药方面。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
CD44v6-mediated regulation of gastric cancer stem cells: a potential therapeutic target.

Gastric cancer is the fourth most common cause of cancer-related deaths globally. Cancer stem cells (CSCs) play an essential role in tumor initiation, development, and chemoresistance. However, the molecular mechanisms that regulate CSC traits in gastric cancer, particularly the role of CD44v6 as a key CSC marker, remain poorly understood. Here, we demonstrate that CD44v6 is markedly upregulated in gastric cancer tissues and correlates with poor prognosis. Functional assays, including colony formation, wound healing, proliferation, and apoptosis assays, show that CD44v6 enhances CSC characteristics, such as self-renewal, proliferation, migration, and cisplatin chemoresistance. CD44v6 knockdown effectively suppresses these aggressive phenotypes. Mechanistically, CD44v6 regulates the expression of key CSC markers, including CD24, CD133, EpCAM, as well as stemness-related transcription factors Oct-4 and Nanog. Additionally, CD44v6 enhances cell proliferation and drug resistance in both in vitro and in vivo experiments. Collectively, our findings highlight the significant role of CD44v6 in regulating gastric CSC traits, suggesting it's a potential as a biomarker and therapeutic target for improving gastric cancer treatment outcomes, particularly in overcoming chemoresistance.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical and Experimental Medicine
Clinical and Experimental Medicine 医学-医学:研究与实验
CiteScore
4.80
自引率
2.20%
发文量
159
审稿时长
2.5 months
期刊介绍: Clinical and Experimental Medicine (CEM) is a multidisciplinary journal that aims to be a forum of scientific excellence and information exchange in relation to the basic and clinical features of the following fields: hematology, onco-hematology, oncology, virology, immunology, and rheumatology. The journal publishes reviews and editorials, experimental and preclinical studies, translational research, prospectively designed clinical trials, and epidemiological studies. Papers containing new clinical or experimental data that are likely to contribute to changes in clinical practice or the way in which a disease is thought about will be given priority due to their immediate importance. Case reports will be accepted on an exceptional basis only, and their submission is discouraged. The major criteria for publication are clarity, scientific soundness, and advances in knowledge. In compliance with the overwhelmingly prevailing request by the international scientific community, and with respect for eco-compatibility issues, CEM is now published exclusively online.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信